Background. The optimal duration of dual antiplatelet therapy (DAPT) after biodegradable-polymer (BP) everolimus-eluting stent (EES) implantation remains uncertain. Methods. This study analyzed 793 patients who underwent percutaneous coronary intervention (PCI) with BP-EES in 10 cardiovascular centers in Korea between July 2016 and January 2018. Using the prescription data at 6 months post-PCI, we divided these patients into two groups, namely, short-DAPT and prolonged-DAPT groups, which underwent DAPT for 6 and > 6 months of PCI, respectively. The primary endpoint, which included mortality, myocardial infarction, or target-vessel revascularization at 2 years, was compared by propensity score (PS) matching between the two groups. Results. Out of the 793 patients, 283 matched pairs were identified by PS matching. Out of this matched population, 405 (71.6%) patients had an acute coronary syndrome. The primary endpoint did not differ in 2 years between the short-DAPT and prolonged-DAPT groups (7.5% vs. 8.3%; hazard ratio, 0.87; 95% confidential interval, 0.47–1.60; ). Likewise, no difference was found regarding mortality, cardiac mortality, myocardial infarction, target-lesion failure, target-vessel failure, and bleeding events defined by the Bleeding Academic Research Consortium and Thrombolysis In the Myocardial Infarction classification. Meanwhile, one patient in the short-DAPT group had definite stent thrombosis at 364 days post-PCI. Subgroup analysis showed that several anatomical and procedural factors were not significantly related to DAPT duration. Most patients (77.4%) in both groups were prescribed clopidogrel at discharge. Conclusions. In real-world patients undergoing PCI with BP-EES, the ischemic and bleeding endpoints demonstrated no difference between 6-month and prolonged (>6 months) DAPT.

中文翻译：

---

可生物降解聚合物依维莫司洗脱支架经皮冠状动脉介入治疗后 6 个月和长期双重抗血小板治疗的比较

背景。生物可降解聚合物 (BP) 依维莫司洗脱支架 (EES) 植入后双重抗血小板治疗 (DAPT) 的最佳持续时间仍不确定。方法。本研究分析了 2016 年 7 月至 2018 年 1 月期间在韩国 10 个心血管中心接受 BP-EES 经皮冠状动脉介入治疗 (PCI) 的 793 名患者。使用 PCI 后 6 个月的处方数据，我们将这些患者分为两组，即、短 DAPT 组和长 DAPT 组，分别接受 DAPT 6 个月和 > 6 个月的 PCI。主要终点包括死亡率、心肌梗死或 2 年时靶血管血运重建，通过两组之间的倾向评分 (PS) 匹配进行比较。结果. 在 793 名患者中，通过 PS 匹配确定了 283 对匹配对。在这个匹配的人群中，405 名 (71.6%) 患者患有急性冠状动脉综合征。短期 DAPT 组和长期 DAPT 组在 2 年内的主要终点没有差异（7.5% 对 8.3%；风险比，0.87；95% 机密区间，0.47-1.60；）。同样，在出血学术研究联盟和心肌梗死分类中的溶栓术定义的死亡率、心脏死亡率、心肌梗死、靶病变衰竭、靶血管衰竭和出血事件方面没有发现差异。同时，短 DAPT 组中的 1 名患者在 PCI 后 364 天有明确的支架血栓形成。亚组分析表明，一些解剖和程序因素与 DAPT 持续时间没有显着相关性。两组中的大多数患者（77.4%）在出院时都服用了氯吡格雷。结论。在接受 BP-EES 的 PCI 的真实世界患者中，缺血和出血终点显示 6 个月和延长（>6 个月）DAPT 之间没有差异。